The Global Lenvatinib Mesylate Market was valued at USD 289.5 Million in 2025 and is projected to reach USD 387.2 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 3.8% during the forecast period (2026–2034). This growth is being driven by the rising global incidence of thyroid, liver, and kidney cancers, coupled with the proven efficacy of lenvatinib-based therapies and the accelerating adoption of high-purity Active Pharmaceutical Ingredients (APIs) in oncology drug manufacturing.

As the pharmaceutical industry advances toward more targeted and effective cancer treatments, the spotlight is on the key API manufacturers who are ensuring the supply, quality, and innovation of critical drug components. In this blog, we profile the Top 10 Companies in the Lenvatinib Mesylate Industry—a mix of established pharmaceutical giants and specialized chemical manufacturers shaping the future of cancer care.

---

🔟 1. Olon Spa

Headquarters: Rodano, Milan, Italy
Key Offering: High-Purity Lenvatinib Mesylate API

Olon Spa is a leading global supplier of active pharmaceutical ingredients, renowned for its expertise in complex oncology compounds. The company has established itself as a key manufacturer of Lenvatinib Mesylate, supplying high-quality API to pharmaceutical companies worldwide. Their focus on rigorous quality control and scalable production makes them a preferred partner for both innovator and generic drug manufacturers.

Manufacturing and Innovation Initiatives:

• Advanced purification technologies for API production
• Strategic partnerships with major global pharma companies
• Investment in continuous manufacturing processes for efficiency

Download FREE Sample Report: Lenvatinib Mesylate Market – View in Detailed Research Report

---

9️⃣ 2. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: Lenvatinib Mesylate API and Formulations

Dr. Reddy’s Laboratories is a globally integrated pharmaceutical company with a strong presence in the oncology API segment. The company leverages its extensive R&D capabilities and manufacturing expertise to produce Lenvatinib Mesylate, catering to the growing demand for this critical oncology ingredient across international markets.

Manufacturing and Innovation Initiatives:

• Vertically integrated manufacturing capabilities
• Focus on developing cost-effective generic versions post-patent expiry
• Global regulatory compliance and approvals

---

8️⃣ 3. MSN Laboratories Private Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: Lenvatinib Mesylate API

MSN Laboratories has emerged as a significant player in the manufacturing of complex APIs, including Lenvatinib Mesylate. The company’s strong R&D focus and state-of-the-art manufacturing facilities position it as a reliable supplier in the global oncology API market, particularly as patents expire and generic competition intensifies.

Manufacturing and Innovation Initiatives:

• Development of efficient synthesis pathways
• Expansion of manufacturing capacity for oncology APIs
• Strategic focus on regulated markets

---

7️⃣ 4. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, Maharashtra, India
Key Offering: Lenvatinib Mesylate API and Finished Dosage Forms

As one of the world’s largest specialty generic pharmaceutical companies, Sun Pharma has a substantial footprint in the oncology API space. The company’s robust manufacturing infrastructure and global distribution network enable it to supply high-quality Lenvatinib Mesylate to markets worldwide, supporting both its own formulations and third-party customers.

Manufacturing and Innovation Initiatives:

• Integrated API and formulation development
• Advanced analytical and quality control laboratories
• Global supply chain optimization

Download FREE Sample Report: Lenvatinib Mesylate Market – View in Detailed Research Report

---

6️⃣ 5. Shilpa Medicare Ltd.

Headquarters: Raichur, Karnataka, India
Key Offering: Lenvatinib Mesylate API

Shilpa Medicare specializes in the development and manufacturing of APIs and intermediates, with a strong focus on oncology drugs. The company has developed capabilities for producing Lenvatinib Mesylate, leveraging its expertise in complex chemical synthesis to serve the growing global demand for this critical cancer therapeutic component.

Manufacturing and Innovation Initiatives:

• Specialization in oncology and hormonal APIs
• Focus on regulatory compliance for international markets
• Custom synthesis and contract manufacturing services

---

5️⃣ 6. Lepu Pharmaceuticals

Headquarters: Beijing, China
Key Offering: Lenvatinib Mesylate API

Lepu Pharmaceuticals is a leading Chinese pharmaceutical company with significant capabilities in oncology drug development and manufacturing. The company has established itself as a key supplier of Lenvatinib Mesylate in the Asian market and is expanding its global footprint through strategic partnerships and regulatory approvals.

Manufacturing and Innovation Initiatives:

• Strong R&D pipeline in oncology therapeutics
• Expansion of international regulatory approvals
• Competitive manufacturing cost structure

---

4️⃣ 7. Nanjing Chia Tai Tianqing Pharmaceutical

Headquarters: Nanjing, Jiangsu, China
Key Offering: Lenvatinib Mesylate API and Formulations

As part of the Sino-American Shanghai Squibb Pharmaceuticals Limited, Nanjing Chia Tai Tianqing has strong technical capabilities in oncology drug manufacturing. The company is positioned as a significant player in the Lenvatinib Mesylate market, particularly serving the growing Chinese pharmaceutical industry and export markets.

Manufacturing and Innovation Initiatives:

• Joint venture expertise with international partners
• Focus on innovative drug delivery systems
• Strong domestic market presence with global aspirations

---

3️⃣ 8. Simcere Pharmaceuticals

Headquarters: Nanjing, Jiangsu, China
Key Offering: Lenvatinib Mesylate API

Simcere Pharmaceutical Group is a leading pharmaceutical company in China with a diversified product portfolio that includes oncology therapeutics. The company has developed manufacturing capabilities for Lenvatinib Mesylate, leveraging its strong R&D foundation and manufacturing expertise to compete in the global API market.

Manufacturing and Innovation Initiatives:

• Integration of R&D, manufacturing, and commercialization
• Focus on first-to-market generic strategies
• Strategic partnerships for market expansion

---

2️⃣ 9. CSPC Ouyi Pharmaceutical

Headquarters: Shijiazhuang, Hebei, China
Key Offering: Lenvatinib Mesylate API

CSPC Ouyi Pharmaceutical is part of the CSPC Pharmaceutical Group, one of China’s leading pharmaceutical manufacturers. The company has established capabilities in producing high-quality oncology APIs, including Lenvatinib Mesylate, serving both domestic and international markets with competitive manufacturing solutions.

Manufacturing and Innovation Initiatives:

• Large-scale manufacturing capabilities
• Focus on cost-effective production processes
• Expansion into regulated international markets

---

1️⃣ 10. Nanjing Hairun Pharmaceutical

Headquarters: Nanjing, Jiangsu, China
Key Offering: Lenvatinib Mesylate API

Nanjing Hairun Pharmaceutical has developed specialized expertise in the synthesis of complex pharmaceutical compounds, including Lenvatinib Mesylate. The company focuses on producing high-purity APIs for the global market, with particular strength in serving the Asian pharmaceutical industry’s growing needs for oncology therapeutics.

Manufacturing and Innovation Initiatives:

• Specialization in complex molecule synthesis
• Quality systems compliant with international standards
• Strategic focus on oncology API portfolio

Get Full Report Here: Lenvatinib Mesylate Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Lenvatinib Mesylate Is Precision and Accessibility

The Lenvatinib Mesylate market is undergoing a significant transformation. While the branded product still dominates in value, the industry is preparing for patent expirations and the subsequent entry of generic versions that will improve treatment accessibility worldwide.

📈 Key Trends Shaping the Market:

• Accelerated generic API development as patents near expiration
• Increasing demand for high-purity (≥99%) APIS for regulatory compliance
• Geographic expansion into emerging markets with growing cancer incidence
• Research into new combination therapies and additional indications

Get Full Report Here: Lenvatinib Mesylate Market – View in Detailed Research Report

The companies listed above are not only supplying critical cancer therapeutics—they’re driving the evolution of precision oncology through quality manufacturing and innovation.